Arianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
New study results found weight loss and diabetes drugs Zepbound and Mounjaro may significantly cut the risk of diabetes in people with prediabetes and obesity, adding to the growing list of diseases researchers have found the drugs can prevent.the results from a three-year study that found its drug tirzepatide slashed the risk of developing type 2 diabetes by 94% in adults with prediabetes who also are obese or overweight.
Tirzepatide is the active ingredient in Mounjaro, the company’s approved diabetes drug, and Zepbound, the company’s approved weight-loss drug. The drug also caused participants to lose weight: Those taking the highest 15 mg dose lost an average of 23% of their body weight compared to the placebo group, which only lost 2.1%.
However, during a 17-week follow up period when participants stopped treatment, weight was regained, and there was “some increase in the progression to type 2 diabetes,” though they still had an 88% reduction in risk, according to Lilly. The most commonly reported adverse events among the study group were mild to moderate gastrointestinal issues like diarrhea, nausea, vomiting and constipation.98 million. That’s about how many Americans have prediabetes, totaling around one in three adults in the U.S., according toPeople with prediabetes have higher than normal blood sugar levels, but they aren’t high enough to be considered type 2 diabetes.
Tirzepatide Mounjaro Eli Lilly Zepbound Prediabetes Zepbound Weight Loss Mounjaro Weight Loss Tirzepatide Weight Loss Weight Loss Drugs Glp1
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
California Goes Off The Rails—AgainSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Could the Nets and Spurs Swap Cam Johnson for Keldon Johnson?NBA trades are still set to happen this offseason.
Read more »